-+ 0.00%
-+ 0.00%
-+ 0.00%

Prestige Biologics Signs USD 11.59 Million Drug Manufacturing Contract

PUBT·11/12/2026 02:14:21
Listen to the news
Prestige Biologics Signs USD 11.59 Million Drug Manufacturing Contract
  • Prestige Biologics signed a KRW 15.5 billion commercial drug substance manufacturing contract on Nov. 12, 2026.
  • The contract represents 58.11% of revenue and runs through Dec. 31, 2027.
  • The customer's identity remains confidential at its request until Dec. 31, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261112900312), on November 12, 2026, and is solely responsible for the information contained therein.